Drug Trial Radar · NCT05467995
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Jun 2, 2021
Primary completion
Apr 25, 2022
Study completion May 19, 2022
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.
Conditions
- Ankylosing Spondylitis
Interventions
AK111Biological
AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
PlaceboBiological
Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects who achieve Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response at Week 16.Time frame: Week16
- Percentage of subjects with treatment-emergent adverse events (TEAEs) during the study.Time frame: Baseline to Week20
- Percentage of subjects with treatment-emergent serious adverse events (SAEs) during the study.Time frame: Baseline to Week20
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital of Bengbu medical college
Bengbu, Anhui, China
Peking university people's hospital
Beijing, Beijing Municipality, China
Peking University Shougang hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Xuanwu hospital capital medical university
Beijing, Beijing Municipality, China
Guangdong provincial people's hospital
Guangzhou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
The first affiliated hospital of Zhengzhou University
Zhengzhou, Henan, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Nanjing Drum Tower hospital
Nanjing, Jiangsu, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The first Bethune hospital of Jilin university
Changchun, Jilin, China
Second hospital of Shanxi Medical university
Taiyuan, Shanxi, China
The seventh affiliated hospital, Sun Yat-sen university
Shenzhen, Shenzhen, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.